Operating Lease, Right-of-Use Asset of Allogene Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Allogene Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Allogene Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $40,935,000, a 12% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Allogene Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $40,935,000 -$5,378,000 -12% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $41,966,000 -$16,419,000 -28% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $44,075,000 -$20,408,000 -32% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $45,205,000 -$18,498,000 -29% 31 Dec 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $46,313,000 -$32,330,000 -41% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $58,385,000 -$21,929,000 -27% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $64,483,000 -$17,481,000 -21% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $63,703,000 -$19,889,000 -24% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $78,643,000 -$6,602,000 -7.7% 30 Sep 2023 10-K 14 Mar 2024 2023 FY
Q2 2023 $80,314,000 -$6,523,000 -7.5% 30 Jun 2023 10-K 14 Mar 2024 2023 FY
Q1 2023 $81,964,000 +$24,907,000 +44% 31 Mar 2023 10-K 14 Mar 2024 2023 FY
Q4 2022 $83,592,000 +$25,562,000 +44% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $85,245,000 +$46,481,000 +120% 30 Sep 2022 10-K 14 Mar 2024 2023 FY
Q2 2022 $86,837,000 +$47,363,000 +120% 30 Jun 2022 10-K 14 Mar 2024 2023 FY
Q1 2022 $57,057,000 +$16,868,000 +42% 31 Mar 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 $58,030,000 +$16,735,000 +41% 31 Dec 2021 10-K/A 14 Mar 2024 2022 FY
Q3 2021 $38,764,000 -$2,793,000 -6.7% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $39,474,000 -$2,958,000 -7% 30 Jun 2021 10-Q 04 Aug 2021 2021 Q2
Q1 2021 $40,189,000 -$3,647,000 -8.3% 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q4 2020 $41,295,000 -$3,200,000 -7.2% 31 Dec 2020 10-K 23 Feb 2022 2021 FY
Q3 2020 $41,557,000 +$10,120,000 +32% 30 Sep 2020 10-Q 04 Nov 2020 2020 Q3
Q2 2020 $42,432,000 +$10,552,000 +33% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 $43,836,000 +$11,442,000 +35% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 $44,495,000 +$11,480,000 +35% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $31,437,000 +$6,441,000 +26% 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $31,880,000 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $32,394,000 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 $33,015,000 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 $24,996,000 30 Sep 2018 10-Q 21 Nov 2018 2018 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.